Shares of Discovery Laboratories Inc. (Nasdaq: DSCO) continued climbing by gaining 69 cents to $4.44 after the Food and Drug Administration approved the biotechnology firm's premature infant respiratory distress syndrome prevention drug Surfaxin yesterday.
